Landmark is a ground-breaking research programme aimed at accelerating the search for new treatments by applying cutting edge techniques to gain a new level of insight at cellular level into the changes Parkinson's causes in the brain. Principal investigator Professor Michael Johnson from Imperial College London explains the need across the global research community for the new high quality datasets his team will produce.

The project will use tissue samples from the Parkinson's UK Brain Bank, which was set up 22 years ago as a result of the remarkable foresight of Professor David Dexter, who is now the charity's Director of Research. He explains what it was like to see his vision come to fruition when Landmark was launched.

The three year research programme brings together a Parkinson's UK led consortium of four major pharmaceutical companies - GSK, Novartis, Roche, and UCB, plus Imperial College London, which was made possible with £4m of funding from the Gatsby charitable foundation.

The ground-breaking Predict-PD study has been gathering valuable information from thirteen thousand volunteers for 15 years, in an effort to find ways of identifying those people most at risk of developing Parkinson’s. We catch up with progress so far and find out how the project is continually growing and swapping information with other researchers as science moves ever closer towards the establishing the causes of the world’s fastest growing neurological disorder.

Dr Alastair Noyce, the Principal Investigator, is Professor of Neurology and Neuroepidemiology at the Queen Mary University of London.

If you are interested in volunteering to take part or just want to find out more, you can do so using this link:

https://predictpd.com/en